Somatostatin-14

Somatostatin-14 (Growth Hormone Inhibiting Factor)

Evidence & Status

  • Strong Human Evidence
  • Strong

At a Glance

The endogenous hypothalamic hormone that broadly suppresses growth hormone, TSH, insulin, glucagon, and multiple gastrointestinal hormones. Breaks down within minutes in the body, limiting direct therapeutic use, but its long-acting analogs Octreotide and Lanreotide are FDA-approved and widely used.

Plain English

Researchers study Somatostatin because it is one of the body's most important inhibitory signals — a single molecule that simultaneously suppresses hormone release across multiple organ systems through a family of five different receptors. Scientists are interested in understanding how such a small peptide can exert such diverse inhibitory control. Because the natural hormone is extremely short-lived, pharmaceutical research has focused on developing longer-acting analogs. Understanding the natural molecule is foundational to understanding how Octreotide, Lanreotide, and Pasireotide achieve their clinical effects.

Overview

Somatostatin-14 is an endogenous cyclic tetradecapeptide produced in the hypothalamus, pancreatic delta cells, and gastrointestinal tract. It has broad inhibitory endocrine and gastrointestinal physiology, including effects on growth hormone, TSH, insulin, glucagon, and multiple GI hormones. Its short native duration contributed to development of longer-acting analogues. Native somatostatin-14 evidence must remain distinct from octreotide, lanreotide, and pasireotide product approvals, dosing, efficacy, pharmacokinetics, and safety.

Research Summary

Somatostatin-14 is a native endocrine and gastrointestinal inhibitory peptide. Human physiology studies describe hormonal and gastric-secretory responses to the native peptide. Its short duration prompted development of longer-acting analogues, but analogue approvals, efficacy, dosing, pharmacokinetics, and safety do not transfer to native somatostatin-14.

Research Areas

  • GH axis regulation
  • Neuroendocrine tumor biology
  • Pancreatic hormone regulation
  • GI physiology
  • Acromegaly research

Safety & Risks

Serious Risks

  • Significant hormonal suppression across multiple axes
  • Glucose dysregulation requiring monitoring
  • Not suitable for unsupervised use due to pleiotropic suppressive effects

Reported Side Effects

  • GI motility reduction (constipation, nausea)
  • Glucose dysregulation (inhibits both insulin and glucagon)
  • Bradycardia
  • Rebound GH hypersecretion after discontinuation
United States
Research only (native form); long-acting analogs are Rx drugs
United Kingdom
Research only (native form)
Australia
Research only (native form)
Canada
Research only (native form)

Citations & Sources